bit.bio Stock
bit.bio represents the two fields coding and biology that determine the identity of every human cell.
Sign up today and learn more about bit.bio Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About bit.bio Stock
bit.bio is an award-winning human synthetic biology enterprise. Our mission is coding cells for health. To do so, we apply the principles of computation to biology. Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modelling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious and driven by a common purpose.
Funding History
| March 2019 | $3.8M |
|---|---|
| February 2020 | $412K |
| February 2020 | $41.1M |
| September 2021 | $3.5M |
| September 2021 | $137M |
Management
Founder
Mark Kotter
CFO & COO
Florian Schuster
Press
pharmafile - Nov, 9 2023
Bit.bio announces cell therapy pipelineendpts - Sep, 1 2023
Exclusive: Stem cell scientist and bit.bio founder launches new startup with goal of extending healthspan by 20 yearsgenengnews - Aug, 25 2023
Synthego, bit.bio Collaborate on Multiplexed Cell Engineering Platformprnewswire - Aug, 4 2023
BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapiesbusinesswire - Jul, 26 2023
bit.bio Secures Foundational United States Patent for opti-oxTM, its Cell Programming Technology That Uses Genomic Safe Harbour Sitespharmiweb - Jun, 12 2023
bit.bio Strengthens Leadership Team With Appointment of Dr Michael Booth as Senior Vice President, External Affairs and Investor Relationsbusinesswire - May, 11 2023
bit.bio Expands Board of Directors With Appointment of Distinguished Investor, Philanthropist, and Scientistbusinesswire - May, 5 2023
Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineeringnews-medical - Jan, 27 2023
bit.bio partners with Automata to automate a key aspect of its production of iPSC derived human cellsbiospace - May, 10 2022
bit.bio Launches Novel Cell Model for Huntington's Diseasesplento - Jan, 20 2022
Top 25 BioTech startupssiliconcanals - Nov, 8 2021
U.K.-based bit.bio secures €89.1M to expedite gene engineering technology to fight diseasesbusinesscloud - Nov, 8 2021
£77m for ‘transformative’ stem cell MedTech bit.bioendpts - Nov, 5 2021
Cell therapy startup bit.bio adds $100M+ to its coffers and some impressive names to its board of directorsbusinesscloud - Oct, 29 2021
Arm founder appointed chair of MedTech bit.biobusinessweekly - Oct, 26 2021
Winter, Hauser, Roemer: Top trio boost bit.bio boardpharmiweb - Oct, 23 2021
bit.bio product launch: ioSkeletal Myocytes; the first supply of consistent, scalable, human muscle cells provide transformative new models for research and drug discoverynanalyze - May, 5 2021
5 Novel Therapies Using Synthetic Biologylaunchticker - Jun, 15 2020
UK-based biotech firm Bit Bio (formerly Elpis Biotechnology) raises $41.5M fromEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
